IRIS
IEZZI, LAURA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.072
EU - Europa 1.547
AS - Asia 954
Continente sconosciuto - Info sul continente non disponibili 192
SA - Sud America 131
AF - Africa 20
OC - Oceania 1
Totale 4.917
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.019
RU - Federazione Russa 758
SG - Singapore 372
CN - Cina 257
IT - Italia 150
IE - Irlanda 129
VN - Vietnam 116
SE - Svezia 110
DE - Germania 103
BR - Brasile 87
FR - Francia 82
UA - Ucraina 75
TR - Turchia 73
GB - Regno Unito 58
IN - India 36
HK - Hong Kong 33
CA - Canada 18
AR - Argentina 15
AT - Austria 15
FI - Finlandia 12
MX - Messico 12
ES - Italia 11
CZ - Repubblica Ceca 10
BD - Bangladesh 9
IQ - Iraq 9
CO - Colombia 8
JP - Giappone 8
PL - Polonia 8
ZA - Sudafrica 7
LT - Lituania 6
NI - Nicaragua 6
PY - Paraguay 6
SA - Arabia Saudita 6
CL - Cile 5
RO - Romania 5
AE - Emirati Arabi Uniti 4
BE - Belgio 4
GT - Guatemala 4
KE - Kenya 4
LB - Libano 4
NL - Olanda 4
UZ - Uzbekistan 4
VE - Venezuela 4
HN - Honduras 3
IL - Israele 3
JO - Giordania 3
PH - Filippine 3
BO - Bolivia 2
EC - Ecuador 2
ET - Etiopia 2
GP - Guadalupe 2
KR - Corea 2
OM - Oman 2
PK - Pakistan 2
PT - Portogallo 2
SC - Seychelles 2
TN - Tunisia 2
UY - Uruguay 2
AF - Afghanistan, Repubblica islamica di 1
AL - Albania 1
AU - Australia 1
AZ - Azerbaigian 1
BG - Bulgaria 1
CR - Costa Rica 1
DK - Danimarca 1
DM - Dominica 1
DO - Repubblica Dominicana 1
DZ - Algeria 1
EE - Estonia 1
EG - Egitto 1
GE - Georgia 1
HU - Ungheria 1
IR - Iran 1
KW - Kuwait 1
LC - Santa Lucia 1
MA - Marocco 1
MQ - Martinica 1
MY - Malesia 1
NP - Nepal 1
SV - El Salvador 1
TH - Thailandia 1
TT - Trinidad e Tobago 1
VG - Isole Vergini Britanniche 1
Totale 4.725
Salva come PNG Salva come JPEG
Città #
Singapore 310
San Jose 243
Chandler 238
Ashburn 154
Dublin 128
Jacksonville 127
Los Angeles 107
Dearborn 90
Beijing 76
Houston 63
Dallas 61
Princeton 52
Munich 43
Council Bluffs 42
Izmir 41
Nanjing 39
Ho Chi Minh City 37
Santa Clara 35
Hong Kong 32
New York 30
Wilmington 29
Chieti 28
Altamura 26
The Dalles 25
Ann Arbor 21
Boardman 20
Dong Ket 20
Hanoi 18
North Bergen 18
Buffalo 17
Southend 16
Moscow 15
Orem 15
São Paulo 15
Cambridge 14
Denver 13
Kunming 13
London 13
Redondo Beach 12
Chicago 11
Washington 11
Frankfurt am Main 10
Nanchang 10
Nuremberg 10
Pescara 10
Atlanta 9
Brno 9
Brooklyn 9
Shenyang 9
St Louis 9
Stockholm 8
Vienna 8
Jiaxing 7
Montreal 7
Mount Pleasant 7
Norwalk 7
Tokyo 7
Warsaw 7
Da Nang 6
Hefei 6
League City 6
Managua 6
Mexico City 6
Tianjin 6
Boston 5
Hebei 5
Helsinki 5
Johannesburg 5
Mumbai 5
Rome 5
Brussels 4
Charlotte 4
Chennai 4
Haiphong 4
Hyderabad 4
Manchester 4
Phoenix 4
Poplar 4
San Francisco 4
Secaucus 4
Tongling 4
Vilnius 4
Woodbridge 4
Zhengzhou 4
Amman 3
Amsterdam 3
Asunción 3
Bogotá 3
Cincinnati 3
Columbus 3
Daly City 3
Falls Church 3
Hangzhou 3
Istanbul 3
Joinville 3
Kyle 3
La Mesa 3
Las Vegas 3
Miami 3
Parma 3
Totale 2.631
Salva come PNG Salva come JPEG
Nome #
"Triple positive" early breast cancer: An observational multicenter retrospective analysis of outcome 943
Impact of BMI on clinical outcome in advanced cancer patients treated with anti‑PD‑1 Immune checkpoint inhibitors: a preliminary analysis 201
A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: a real-world experience 191
Neoadjuvant chemotherapy in triple-negative breast cancer: A multicentric retrospective observational study in real-life setting 183
Combination of peripheral neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio is predictive of pathological complete response after neoadjuvant chemotherapy in breast cancer patients 183
Body Mass Index and Treatment Outcomes in Metastatic Breast Cancer Patients Treated With Eribulin 177
A Case of Stage I Vulvar Squamous Cell Carcinoma with Early Relapse and Rapid Disease Progression 177
Trastuzumab Emtansine (T-DM1) in Patients (pts) With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (MBC): results From a Multicenter Retrospective Analysis 161
Effect of Gender on the Outcome of Patients Receiving Immune Checkpoint Inhibitors for Advanced Cancer: A Systematic Review and Meta-Analysis of Phase III Randomized Clinical Trials 157
Body mass index modifies the relationship between γ-H2AX, a DNA damage biomarker, and pathological complete response in triple-negative breast cancer 156
Fulvestrant (FUL) 500 milligrams as endocrine therapy (ET) for hormone sensitive advanced breast cancer patients (pts). The Ful500 prospective observational trial 151
Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor-positive, advanced breast cancer: A real-world experience 150
Long-term outcome of neoadjuvant endocrine therapy with aromatase inhibitors in elderly women with hormone receptor-positive breast cancer 146
Fasting glucose and body mass index as predictors of activity in breast cancer patients treated with everolimus-exemestane: The EverExt study 146
Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting 145
Fulvestrant 500 milligrams as endocrine therapy for endocrine sensitive advanced breast cancer patients in the real world: the Ful500 prospective observational trial. 142
Anthropometric, clinical and molecular determinants of treatment outcomes in postmenopausal, hormone receptor positive metastatic breast cancer patients treated with fulvestrant: Results from a real word setting 142
Predictive factors of response to neoadjuvant chemotherapy (NAT) in triple negative breast (TNBC) cancer patients: A restrospective multicenter observational study. 140
Outcomes of HER2-positive early breast cancer patients in the pre-trastuzumab and trastuzumab eras: a real-world multicenter observational analysis. The RETROHER study 138
Do cut-off values of lymph node ratio and presence of perineural invasion affect survival in breast cancer patients with pathologic N3a lymph node stage? Reply to Kadri Altundag 138
A multicenter REtrospective observational study of first-line treatment with PERtuzumab, trastuzumab and taxanes for advanced HER2 positive breast cancer patients. RePer Study 138
Long-term outcome of breast cancer patients with pathologic N3a lymph node stage 134
Weight loss and body mass index in advanced gastric cancer patients treated with second-line ramucirumab: a real-life multicentre study 132
Safety analysis, association with response and previous treatments of everolimus and exemestane in 181 metastatic breast cancer patients: A multicenter Italian experience 126
Triple positive early breast cancer in the pre- and post Trastuzumab eras: a subgroup analysis of a multicenter retrospective study. 118
Prognostic Relevance of Neutrophil to Lymphocyte Ratio (NLR) in Luminal Breast Cancer: A Retrospective Analysis in the Neoadjuvant Setting 113
Prognostic relevance of DNA damage and repair biomarkers in elderly patients with hormone-receptor-positive breast cancer treated with neoadjuvant hormone therapy: evidence from the real-world setting 100
PANHER study: a 20-year treatment outcome analysis from a multicentre observational study of HER2-positive advanced breast cancer patients from the real-world setting 89
Totale 4.917
Salva come PNG Salva come JPEG
Categoria #
all - tutte 16.259
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 16.259
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022103 0 0 0 0 6 4 6 8 9 4 15 51
2022/2023561 38 75 38 77 48 100 22 55 69 7 21 11
2023/2024268 31 13 17 11 19 99 38 5 6 10 3 16
2024/2025458 30 67 63 27 10 42 17 24 48 36 46 48
2025/20262.056 99 42 109 161 157 96 292 69 790 121 81 39
2026/2027447 87 56 98 132 74 0 0 0 0 0 0 0
Totale 4.917